AI in Epigenetics Market Size, Share, Opportunities, And Trends By Technology (DNA Methylation, Histone Modification, Non-Coding RNA Analysis, Chromatin Accessibility), By Application (Oncology, Non-Oncology), By End-User (Academic & Research Institutions, Pharmaceutical & Biotechnology Companies, Clinical Laboratories, Hospitals & Clinics), And By Geography - Forecasts From 2025 To 2030

AI in the Epigenetics Market Size:

The AI in the epigenetics market is expected to grow steadily over the forecasted timeframe.

The market for AI in epigenetics is expanding at a steady rate. This is because scientists and medical professionals use AI to speed up discoveries in the regulation of gene expression. Epigenetics is making changes to DNA and histones that affect gene activity without changing the genetic code. Artificial intelligence (AI) technologies, particularly machine learning and deep learning, are being used to analyse complex multi-omics data, find biomarkers, and uncover patterns. These patterns pertain to ageing, disease development, and response to treatment. AI helps in finding out how epigenetic modifications can impact tumour growth. They can also help in treatment resistance in domains such as cancer research.

Additionally, combining sizable datasets from genomics, epigenomics, and clinical records is a critical part of this market. AI-powered tools help in drug discovery, diagnostics, and personalised medicine. AI is making epigenetics a more predictive and focused field of study as data becomes more accessible.

AI in Epigenetics Market Overview & Scope:

The AI in the epigenetics market is segmented by:

• Technology: DNA methylation holds a significant share of the AI in the epigenetics market. This is because it is one of the most well-studied and impactful epigenetic modifications. It is also linked to gene regulation and disease development. Changes in methylation patterns are strongly associated with conditions such as cancer, autoimmune disorders, and neurological diseases
• Application: Oncology holds a considerable share of the AI in the epigenetics market. This is due to the crucial role epigenetic modifications like DNA methylation have to play in the advancement of cancer. They are primarily used to identify cancer-specific biomarkers, understand tumour heterogeneity, and predict treatment responses.
• End User: Academic and research institutions hold a substantial share of the AI in the epigenetics market. This is because they have a huge role to play in the development of both epigenetics research and AI technologies. These institutions conduct many research studies revolving around gene regulation mechanisms and develop novel biomarkers
• Region: The Asia-Pacific AI in epigenetics market is witnessing strong growth. This is driven by increasing investments in biotech research, AI-driven healthcare, and the digitisation of genomic data. Countries like India and China are the key players in this market. This is because of national genomics initiatives, expanding AI capabilities, and rising demand for precision medicine

Top Trends Shaping the AI in Epigenetics Market:

1. Integration of Multi-Omics Data for Holistic Insights: A trend in AI in the epigenetics market is the integration of multi-omics data for holistic insights. This holistic approach enables researchers to gain a comprehensive understanding of biological systems and disease mechanisms. This is leading to better biomarker discovery, personalised treatments, and precision diagnostics.

2. AI-Driven Drug Discovery and Development- Another significant trend is the AI-driven drug discovery. Pharmaceutical companies are integrating AI with epigenetic data to develop epigenetic inhibitors and personalised drugs. According World Journal of Advanced Research and Reviews, 2024 AI-driven drug discovery costs around $100M-$500M which is way less than traditional drug discovery due to the benefits of automation.

3. Development of Explainable and Interpretable AI Models: There has been an increase in the development of explainable and interpretable AI models. Explainable AI tools provide transparent and interpretable results. They are also useful for biomarker validation and treatment planning.

AI in Epigenetics Market Growth Drivers vs. Challenges:

Drivers:

•  Growth of High-Throughput Omics Technologies: One of the key drivers of the AI in epigenetics market is the growth in high-throughput omics technologies. This has led to a large set of complex biological data, including DNA methylation, histone modification, and chromatin accessibility datasets. According to the National Library of Medicine 2024 report, the integration of genetic variants, DNA methylation, and gene expression data in bladder cancer research has identified 48 genes with SNPs and CpGs. 75% of these results can be recreated through an independent dataset.
• Growing Investment in Life Sciences and AI Integration: Another key driver of AI in the epigenetic market is the growth in investment in life sciences and AI integration. Initiatives like The Cancer Genome Atlas and international epigenome mapping efforts are producing massive datasets that require AI for effective analysis. According to Bessemer’s 2024 report, hospitals invest around $36 billion every year on IT, including hardware, software and human resources.

Challenges:

• Data Heterogeneity: One of the major challenges of AI in the epigenetic market is data heterogeneity and complexity. Epigenetic modifications such as DNA methylation, histone modifications, and chromatin remodelling are dynamic. Applying AI to this data required advanced algorithms that can process and learn from multi-dimensional and time-dependent biological patterns. However, this market faces many problems in terms of data standardisation, harmonisation, and quality control. This delays the regulatory approval and practical applications in diagnostics and therapeutics. This slows the pace of innovation and adoption across the healthcare and pharmaceutical sectors.

AI in Epigenetics Market Regional Analysis:

• United States: The USA is considered to have the largest share of the global epigenetic market. The country leads due to its robust biotechnology sector, significant R&D investments, and presence of key players like Illumina, Thermo Fisher Scientific, PacBio, Chroma Medicine, and FOXO Technologies.
• Germany: Germany is a major player in Europe’s epigenetics market. This is due to the leadership in precision medicine and biotechnology.
• China:  China is a rapidly growing market in Asia-Pacific. This is due to investment in genomics and AI technologies. These investments help the adoption and growth of the market in the country.
• United Kingdom: The UK is a key player in Europe, with a strong focus on epigenetic research for drug discovery and diagnostics.

AI in Epigenetics Market Competitive Landscape:

The market has many notable players, including. FOXO Technologies, DNAstack, Epigenica, Chroma Medicine, Moonwalk Biosciences, PacBio, Illumina, Inc., Thermo Fisher Scientific, among others.

• Funding: In March 2025, Decibel Bio announced that it had secured $12 million. This funding will be used to advance the epigenetic plant programming platform. This would help farmers to apply a treatment to boost the genes that will protect it from extreme heat.

AI in Epigenetics Market Segmentation:

By Technology

• DNA Methylation
• Histone Modification
• Non-Coding RNA Analysis
• Chromatin Accessibility

By Application

• Oncology
• Non-Oncology

By End-User

• Academic & Research Institutions
• Pharmaceutical & Biotechnology Companies
• Clinical Laboratories
• Hospitals & Clinics

By Region

• North America
  • USA
  • Canada
  • Mexico
• South America
  • Brazil
  • Argentina
  • Others
• Europe
  • United Kingdom
  • Germany
  • France
  • Italy
  • Spain
  • Others
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • Others
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Thailand
  • Others

1. EXECUTIVE SUMMARY 

2. MARKET SNAPSHOT

2.1. Market Overview

2.2. Market Definition

2.3. Scope of the Study

2.4. Market Segmentation

3. BUSINESS LANDSCAPE 

3.1. Market Drivers

3.2. Market Restraints

3.3. Market Opportunities 

3.4. Porter’s Five Forces Analysis

3.5. Industry Value Chain Analysis

3.6. Policies and Regulations 

3.7. Strategic Recommendations 

4. TECHNOLOGICAL OUTLOOK 

5. AI IN EPIGENETICS MARKET BY TECHNOLOGY

5.1. Introduction

5.2. DNA Methylation

5.3. Histone Modification

5.4. Non-Coding RNA Analysis

5.5. Chromatin Accessibility

6. AI IN EPIGENETICS MARKET BY APPLICATION

6.1. Introduction

6.2. Oncology

6.3. Non-Oncology 

7. AI IN EPIGENETICS MARKET BY END-USER

7.1. Introduction

7.2. Academic & Research Institutions

7.3. Pharmaceutical & Biotechnology Companies

7.4. Clinical Laboratories

7.5. Hospitals & Clinics

8.  AI IN EPIGENETICS MARKET BY GEOGRAPHY

8.1. Introduction

8.2. North America

8.2.1. USA

8.2.2. Canada

8.2.3. Mexico

8.3. South America

8.3.1. Brazil 

8.3.2. Argentina

8.3.3. Others

8.4. Europe

8.4.1. United Kingdom

8.4.2. Germany

8.4.3. France

8.4.4. Italy

8.4.5. Spain

8.4.6. Others

8.5. Middle East & Africa

8.5.1. Saudi Arabia

8.5.2. UAE

8.5.3. Others

8.6. Asia Pacific

8.6.1. China

8.6.2. India

8.6.3. Japan

8.6.4. South Korea

8.6.5. Thailand

8.6.6. Others

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

9.1. Major Players and Strategy Analysis

9.2. Market Share Analysis

9.3. Mergers, Acquisitions, Agreements, and Collaborations

9.4. Competitive Dashboard

10. COMPANY PROFILES

10.1. FOXO Technologies

10.2. DNAstack

10.3. Chroma Medicine

10.4. Moonwalk Biosciences

10.5. PacBio

10.6. Illumina, Inc.

10.7. Thermo Fisher Scientific

10.8. Merck KGaA

10.9. QIAGEN 

10.10. EPIX.AI 

11. APPENDIX

11.1. Currency 

11.2. Assumptions

11.3. Base and Forecast Years Timeline

11.4. Key benefits for the stakeholders

11.5. Research Methodology 

11.6. Abbreviations 

FOXO Technologies

DNAstack

Chroma Medicine

Moonwalk Biosciences

PacBio

Illumina, Inc.

Thermo Fisher Scientific

Merck KGaA

QIAGEN 

EPIX.AI